Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 4/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | PRF1 | P14222 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14162676 | 0.92 | MAPKAPK5 (0.57) | MAPKAPK5MAP4K1TBK1GSK3BTGFBR1 | |
| SCHEMBL10133651 | 0.89 | MAPKAPK5 (0.51) | MAPKAPK5MAP4K1 | |
| SCHEMBL10133626 | 0.87 | MAPKAPK5 (0.54) | MAPKAPK5MAP4K1TBK1GSK3BPRKCI | |
| SCHEMBL12424130 | 0.86 | MAPKAPK5 (0.50) | MAPKAPK5MAP4K1TBK1GSK3BPRKCI | |
| SCHEMBL10133603 | 0.85 | MAPKAPK5 (0.46) | MAPKAPK5MAP4K1ALOX5APFEN1 | |
| SCHEMBL10133621 | 0.84 | MAPKAPK5 (0.55) | MAPKAPK5MAP4K1TBK1GSK3BPRKCI | |
| SCHEMBL10133644 | 0.84 | MAPKAPK5 (0.49) | MAPKAPK5TBK1GSK3BPRKCITGFBR1 | |
| SCHEMBL10133624 | 0.83 | MAPKAPK5 (0.66) | MAPKAPK5MAP4K1TBK1GSK3BPRKCI | |
| SCHEMBL10133649 | 0.83 | MAPKAPK5 (0.58) | MAPKAPK5MAP4K1TBK1GSK3BTGFBR1 | |
| SCHEMBL1685135 | 0.81 | MAPKAPK5 (0.60) | MAPKAPK5MAP4K1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885MAP4K1 86/4885TBK1 1968/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885MAP4K1 86/4885TBK1 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.